 WATERTOWN, Mass., June 10, 2022 GLOBE NEWSWIRE -- EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT, a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that a late-breaking abstract highlighting 12-month data from the Phase 1 DAVIO clinical trial evaluating EYP-1901 for the treatment of wet age-related macular degeneration wet AMD has been selected for presentation at the American Society of Retinal Specialists ASRS 2022 Annual Meeting to be held in New York City from July 13 16, 2022. 